Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | USP2 | O75604 | 3/20 | 0.82 |
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.82 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | RECQL | P46063 | 3/20 | 0.82 |
| ▸ | BLM | P54132 | 3/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678764 | 0.90 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL29429711 | 0.90 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL2678765 | 0.90 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL2678762 | 0.90 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL18292349 | 0.85 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL6045468 | 0.82 | EGFR (0.83) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL15075269 | 0.82 | EGFR (0.83) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL10241964 | 0.81 | EGFR (0.74) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL31060696 | 0.79 | EGFR (1.00) | EGFRERBB2KDM4EMEN1ALDH1A1 | |
| SCHEMBL11327223 | 0.79 | MEN1 (0.71) | EGFRERBB2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326839-A1 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| EP-4255567-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4192881-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| US-20230082623-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. | 2023-03-16 | — | — | US | claimed |
| WO-2022120390-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022032293-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20240270843-A1 | TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF | VIGIL NEUROSCIENCE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4347658-A1 | TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF | Vigil Neuoscience, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4277992-A1 | CELL ENGINEERING COMPOSITIONS AND METHODS USING FLUOROGENIC OLIGONUCLEOTIDE SIGNALING PROBES AND FLOW CYTOMETRY | SECONDCELL BIO, LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4255567-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4192881-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230082623-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022251868-A1 | TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF | VIGIL NEUROSCIENCE, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022155477-A1 | CELL ENGINEERING COMPOSITIONS AND METHODS USING FLUOROGENIC OLIGONUCLEOTIDE SIGNALING PROBES AND FLOW CYTOMETRY | SECONDCELL BIO, LLC (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022120390-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022032293-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270843-A1 | TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF | APP, CHRNB2, BACE2 | EGFR 1428/4885ERBB2 310/4885KDM4E 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.